XSHG
600613
Market cap587mUSD
Oct 09, Last price
8.72CNY
1D
6.34%
1Q
84.36%
Jan 2017
-37.85%
Name
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
Chart & performance
P/E
109.29
P/S
2.14
EPS
0.08
Div yield, %
1.83%
Shrs. gr., 5y
0.49%
Rev. gr., 5y
1.43%
Revenues
1.95b
-4.71%
Net income
38m
-46.43%
CFO
124m
-40.10%
Dividend
Jun 17, 20260.07 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., through its various subsidiaries, functions as a pharmaceutical manufacturing holding and investment entity within China. The company's operations encompass the research, development, and production of a broad spectrum of medications. Its therapeutic focus includes pharmaceuticals for oncology, cardiovascular and cerebrovascular conditions, respiratory issues (such as colds and coughs), pediatric care, and antifungal treatments, alongside general health tonics. The firm's product portfolio features both prescription-only drugs and readily available over-the-counter (OTC) remedies. Established in Shanghai, China, in 1992, the company continues to operate from this location.
Key people
Famiao Li
Chief Financial Officer · since 2020
Bin Feng
General Manager, Director · since 2011
Kejing Wu
Secretary of the Board, Director · since 2017
Tao Wu
Director
Dan Xu
Director · since 2017
Zhiting Zhang
Chairman of the Board · since 2020
Taotao Zhang
Vice Chairman of the Board · since 2020
Shigui Chen
Independent Director · since 2020
Congyan Li
Independent Director · since 2020
Ning Zhou
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||